Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partners PrEP: TDF and FTC/TDF for HIV Prevention
NCT00557245Phase 3Completed
- Sponsor
- University of Washington
- Start
- May 2008
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing TDF, FTC/TDF and Placebo (3 arms). Primary endpoints: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants at 36 months and Number of Participants With Serious Adverse Events (SAEs) at 36 months. Started May 2008; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00557245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557245.